Joan L. Warren
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Joan L. Warren has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
- Angel M. Cronin
Division of Population Science, Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, MA, 02215, USA
1 shared publication Cathy J. Bradley
Department of Health SystemsManagement, and Policy, Colorado Comprehensive Cancer Center, University of Colorado, Aurora, CO †Health Services and Economics BranchNational Cancer Institute, Bethesda, MD ‡Information Management ServicesRockville, MD §Departments of Medicine and Health Care Policy, Massachusetts General Hospital Cancer Center and Harvard Medical SchoolBoston, MA
1 shared publication- Christopher Bs Zeruto
Information Management Services Inc., Calverton, MD
1 shared publication - Christopher S. Saigal
Department of Urology, David Geffen School of Medicine at UCLA, Los Angeles, CA
1 shared publication - David C. Miller
Department of Urology, University of Michigan, Ann Arbor, MI
1 shared publication - Deborah Schrag
Dana-Farber Cancer Institute, Boston, MA
1 shared publication
Latest Publications
- 1 January 2017
- Published by Wolters Kluwer Health in Medical Care
- Vol. 55 (1) , 86-87
Use of High-cost Systemic Treatments in Elderly mCRC Patients
- 1 January 2017
- Published by Wolters Kluwer Health in Medical Care
- Vol. 55 (1) , 86-87
Use of High-cost Systemic Treatments in Elderly mCRC Patients
- 1 October 2014
- Published by Wolters Kluwer Health in Medical Care
- Vol. 52 (10) , e65-e73
Validating Billing/Encounter Codes as Indicators of Lung, Colorectal, Breast, and Prostate Cancer Recurrence Using 2 Large Contemporary Cohorts
Background: A substantial proportion of cancer-related mortality is attributable to recurrent, not de novo metastatic disease, yet we know relatively little about these patients. To fill this gap, investigators often use administrative codes for secondary malignant neoplasm or chemotherapy to identify recurrent cases in population-based datasets. However, these algorithms have not been validated in large, contemporary, routine care cohorts. Objective: To evaluate the validity of secondary malignant neoplasm and chemotherapy codes as indicators of recurrence after definitive local therapy for stage I–III lung, colorectal, breast, and prostate cancer. Research Design, Subjects, and Measures: We assessed the sensitivity, specificity, and positive predictive value (PPV) of these codes 14 and 60 months after diagnosis using 2 administrative datasets linked with gold-standard recurrence status information: CanCORS/Medicare (diagnoses 2003–2005) and HMO/Cancer Research Network (diagnoses 2000–2005). Results: We identified 929 CanCORS/Medicare patients and 5298 HMO/CRN patients. Sensitivity, specificity, and PPV ranged widely depending on which codes were included and the type of cancer. For patients with lung, colorectal, and breast cancer, the combination of secondary malignant neoplasm and chemotherapy codes was the most sensitive (75%–85%); no code-set was highly sensitive and highly specific. For prostate cancer, no code-set offered even moderate sensitivity (≤19%). Conclusions: Secondary malignant neoplasm and chemotherapy codes could not identify recurrent cancer without some risk of misclassification. Findings based on existing algorithms should be interpreted with caution. More work is needed to develop a valid algorithm that can be used to characterize outcomes and define patient cohorts for comparative effectiveness research studies.
- 1 October 2014
- Published by Wolters Kluwer Health in Medical Care
- Vol. 52 (10) , e65-e73
Validating Billing/Encounter Codes as Indicators of Lung, Colorectal, Breast, and Prostate Cancer Recurrence Using 2 Large Contemporary Cohorts
Background: A substantial proportion of cancer-related mortality is attributable to recurrent, not de novo metastatic disease, yet we know relatively little about these patients. To fill this gap, investigators often use administrative codes for secondary malignant neoplasm or chemotherapy to identify recurrent cases in population-based datasets. However, these algorithms have not been validated in large, contemporary, routine care cohorts. Objective: To evaluate the validity of secondary malignant neoplasm and chemotherapy codes as indicators of recurrence after definitive local therapy for stage I–III lung, colorectal, breast, and prostate cancer. Research Design, Subjects, and Measures: We assessed the sensitivity, specificity, and positive predictive value (PPV) of these codes 14 and 60 months after diagnosis using 2 administrative datasets linked with gold-standard recurrence status information: CanCORS/Medicare (diagnoses 2003–2005) and HMO/Cancer Research Network (diagnoses 2000–2005). Results: We identified 929 CanCORS/Medicare patients and 5298 HMO/CRN patients. Sensitivity, specificity, and PPV ranged widely depending on which codes were included and the type of cancer. For patients with lung, colorectal, and breast cancer, the combination of secondary malignant neoplasm and chemotherapy codes was the most sensitive (75%–85%); no code-set was highly sensitive and highly specific. For prostate cancer, no code-set offered even moderate sensitivity (≤19%). Conclusions: Secondary malignant neoplasm and chemotherapy codes could not identify recurrent cancer without some risk of misclassification. Findings based on existing algorithms should be interpreted with caution. More work is needed to develop a valid algorithm that can be used to characterize outcomes and define patient cohorts for comparative effectiveness research studies.
- 1 May 2013
- Published by Wolters Kluwer Health in Medical Care
- Vol. 51 (5) , e27-e34
Identifying Specific Chemotherapeutic Agents in Medicare Data
Background: Large health care databases are increasingly used to examine the dissemination and benefits and harms of chemotherapy treatment in routine practice, particularly among patients excluded from trials (eg, the elderly). Misclassification of chemotherapy could bias estimates of frequency and association, warranting an updated assessment. Methods: We evaluated the validity of Medicare claims to identify receipt of chemotherapy and specific agents delivered to elderly stage II/III colorectal (CRC), in situ/early-stage breast, non-small–cell lung, and ovarian cancer patients using the National Cancer Institute’s Patterns of Care studies (POC) as the gold standard. The POC collected data on chemotherapy treatment by reabstracting hospital records, contacting physicians, and reviewing medical records. Patients’ POC data were linked and compared with their Medicare claims for 2 to 12 months postdiagnosis. κ, sensitivity, specificity, positive and negative predictive values and 95% confidence intervals were calculated for the receipt of any chemotherapy and specific agents. Results: Sensitivity and specificity of Medicare claims to identify any chemotherapy were high across all cancer sites. We found substantial variation in validity across agents, by site and administration modality. Capecitabine, an oral CRC treatment, was identified in claims with high specificity (98%) but low sensitivity (47%), whereas oxaliplatin, an intravenously administered CRC agent had higher sensitivity (75%) and similar specificity (97%). Conclusions: Receipt of chemotherapy and specific intravenous agents can be identified using Medicare claims, showing improvement from prior reports; yet, variation exists. Future studies should assess newly approved agents and the impact of coverage decisions for these agents under the Medicare Part D program.
- 1 May 2013
- Published by Wolters Kluwer Health in Medical Care
- Vol. 51 (5) , e27-e34
Identifying Specific Chemotherapeutic Agents in Medicare Data
Background: Large health care databases are increasingly used to examine the dissemination and benefits and harms of chemotherapy treatment in routine practice, particularly among patients excluded from trials (eg, the elderly). Misclassification of chemotherapy could bias estimates of frequency and association, warranting an updated assessment. Methods: We evaluated the validity of Medicare claims to identify receipt of chemotherapy and specific agents delivered to elderly stage II/III colorectal (CRC), in situ/early-stage breast, non-small–cell lung, and ovarian cancer patients using the National Cancer Institute’s Patterns of Care studies (POC) as the gold standard. The POC collected data on chemotherapy treatment by reabstracting hospital records, contacting physicians, and reviewing medical records. Patients’ POC data were linked and compared with their Medicare claims for 2 to 12 months postdiagnosis. κ, sensitivity, specificity, positive and negative predictive values and 95% confidence intervals were calculated for the receipt of any chemotherapy and specific agents. Results: Sensitivity and specificity of Medicare claims to identify any chemotherapy were high across all cancer sites. We found substantial variation in validity across agents, by site and administration modality. Capecitabine, an oral CRC treatment, was identified in claims with high specificity (98%) but low sensitivity (47%), whereas oxaliplatin, an intravenously administered CRC agent had higher sensitivity (75%) and similar specificity (97%). Conclusions: Receipt of chemotherapy and specific intravenous agents can be identified using Medicare claims, showing improvement from prior reports; yet, variation exists. Future studies should assess newly approved agents and the impact of coverage decisions for these agents under the Medicare Part D program.
- Open Access
- 26 July 2012
- Published by Springer Nature in BMC Nephrology
- Vol. 13 (1) , 65
Cancer risk among elderly persons with end-stage renal disease: a population-based case–control study
Patients with end-stage renal disease (ESRD) have elevated cancer risk. Cancer risk increases with age, but associations of ESRD with specific malignancies are incompletely studied for older individuals.
- 26 July 2012
- Published by Springer Nature in BMC Nephrology
- Vol. 13 (1) , 65
Open AccessCancer risk among elderly persons with end-stage renal disease: a population-based case–control study
Patients with end-stage renal disease (ESRD) have elevated cancer risk. Cancer risk increases with age, but associations of ESRD with specific malignancies are incompletely studied for older individuals.
- Open Access
- 6 June 2009
- Published by Springer Nature in BMC Health Services Research
- Vol. 9 (1) , 92
External validation of a claims-based algorithm for classifying kidney-cancer surgeries
Unlike other malignancies, there is no literature supporting the accuracy of medical claims data for identifying surgical treatments among patients with kidney cancer. We sought to validate externally a previously published Medicare-claims-based algorithm for classifying surgical treatments among patients with early-stage kidney cancer. To achieve this aim, we compared procedure assignments based on Medicare claims with the type of surgery specified in SEER registry data and clinical operative reports.
- 6 June 2009
- Published by Springer Nature in BMC Health Services Research
- Vol. 9 (1) , 92
Open AccessExternal validation of a claims-based algorithm for classifying kidney-cancer surgeries
Unlike other malignancies, there is no literature supporting the accuracy of medical claims data for identifying surgical treatments among patients with kidney cancer. We sought to validate externally a previously published Medicare-claims-based algorithm for classifying surgical treatments among patients with early-stage kidney cancer. To achieve this aim, we compared procedure assignments based on Medicare claims with the type of surgery specified in SEER registry data and clinical operative reports.